雑誌文献を検索します。書籍を検索する際には「書籍検索」を選択してください。

検索

書誌情報 詳細検索 by 医中誌

Japanese

Efficacy and safety of selective prostaglandin EP2 agonist in primary open angle glaucoma and ocular hypertension Jun Kozaki 1 , Naoyuki Maeda 1 , Ryo Kosaki 1 1Kozaki Eye Clinic pp.85-92
Published Date 2022/1/15
DOI https://doi.org/10.11477/mf.1410214275
  • Abstract
  • Look Inside
  • Reference

Abstract Purpose:To investigate the efficacy and safety of a topical selective prostaglandin EP2 agonist for treating primary open angle glaucoma(POAG)and ocular hypertension.

Methods:One hundred and twenty seven eyes of 127 patients with POAG or ocular hypertension were included in this study. The lowering of intraocular pressure(IOP)by the topical selective prostaglandin EP2 agonist was evaluated in 21 naïve eyes. The changes in IOP and incidence of prostaglandin associated periorbitopathy(PAP)were evaluated in the patients whose glaucoma eyedrops were switched to the selective prostaglandin EP2 agonist.

Results:In the naïve eyes, IOP decreased by an average of 4.1 mmHg, and the IOP reduction rate was 17.8%. Non-responder accounted for 16.3% of the patients. The group that received beta-blockers showed reduction in IOP by 2.0 mmHg and did not show any PAP symptoms. The change from the conventional prostaglandin(PG)eyedrops to selective prostaglandin EP2 agonist reduced PAP by 90%, with no significant changes in IOP. There was no significant change in IOP in the group that switched from the PG combination drug, and the incidence of PAP was decreased by 76%.

Conclusion:The selective prostaglandin-EP2 receptor agonist eyedrops had a similar IOP-lowering effect as that of conventional PGs, while also reducing PAP. Therefore, it is promising as a therapeutic agent for POAG and ocular hypertension.


Copyright © 2022, Igaku-Shoin Ltd. All rights reserved.

基本情報

電子版ISSN 1882-1308 印刷版ISSN 0370-5579 医学書院

関連文献

もっと見る

文献を共有